Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (June 2026)
43 slides from Ac Immune Sa's shareholder meeting presentation, Jun 11, 2026
Slide 1: Investor Update: Annual General Meeting – June 11, 2026
NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission Investor Update NASDAQ: ACIU | Annual General Meeting – June 11, 2026 PIONEERING PRECISION PREVENTION TARGETED THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
Slide 2: Disclaimer
Disclaimer 2 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission This presentation contains statements that constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the
Slide 3: Agenda
Agenda AC Immune’s approach to neurodegenerative diseases 1. Achievements 2025 2. Business update 3. Key milestones 2026 4. Financial figures 5. Summary and Strategic outlook 6. Agenda items and proposals of the Board of Directors 7. 3 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune.
Slide 4: AC Immune's approach to neurodegenerative diseases
1. AC Immune’s approach to neurodegenerative diseases
Slide 5: AC Immune – pioneering precision prevention of neurodegeneration
Differentiated technology platforms validated through multiple clinical candidates and pharma partnering deals Partnering: strategic, risk - mitigating, timely, monetization with >CHF 4.3 billion in potential milestones Cash reserves on Balance sheet Funding into Q4 2027 AC Immune – pioneering preci
Slide 6: Achievements 2025
2. Achievements 2025
Slide 7: AC Immune 2025 highlights
AC Immune 2025 highlights Cash runway permits achievement of key milestones & execution of value - generating innovation Finance Targeted active immunotherapies: ▪ ACI - 7104 1 (wholly - owned) Phase 2 trial interims with potential disease - modifying activity ▪ ACI - 24 2 (Takeda) ABATE cohort comp
Slide 8: Business update
3. Business update
Slide 9: Our value drivers achieving Precision Prevention
Our value drivers achieving Precision Prevention through Active Immunotherapy complemented by Intracellular Targeting The only active immunotherapy in a prevention study for pre - symptomatic Alzheimer’s disease ACI - 35.030 anti - pTau Biomarker - driven development targeting the hallmark protein i
Slide 10: Pipeline focused on Precision Prevention for neurodegenerative diseases
PI - 2620 Alzheimer's disease, PSP 5 and others ( Tau ) Tracer FDA Fast Track Active Immunotherapy Modality Candidate Partner Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 ACI - 35.030 (JNJ - 2056) Alzheimer's disease ( pTau 1 ) ACI - 24.060 Alzheimer's disease ( Abeta 2 ) Alzheimer's dis
Slide 11: Active immunotherapy programs: Targeting Abeta, Tau, and a-syn
Active immunotherapy programs: Targeting intracellular Abeta, Tau, and a - syn
Slide 12: Active immunotherapy targeting neurodegenerative diseases: major advantages
targeting neurodegenerative diseases Long - lasting specific immunity for pathological target, consistent, boostable Limited annual dosing (once or twice) after priming year No observed ARIA - E 1 to date (safety profile well suited to long - term use) Ease of administration and simple logistics for
Slide 13: Active immunotherapies driving Precision Prevention
(1) Alzheimer’s disease; (2) Down syndrome - related Alzheimer’s disease; (3) alpha - synuclein; (4) Parkinson’s disease Active immunotherapies driving Precision Prevention Three clinical - stage programs supported by promising data from prior trials ACI - 35 anti - pTau ACI - 24 anti - Abeta ACI -
Slide 14: Active immunotherapy: a new class of treatment for neurodegenerative disease
Active immunotherapy: a new class of treatment for neurodegenerative disease Potential for profound social and economic impact Treatment Maintenance Prevention for global treatment and prevention of neurodegenerative diseases 14 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to
Slide 15: Small molecule programs: Targeting intracellular NLRP3, Tau, and a-syn
Small molecule programs: Targeting intracellular NLRP3, Tau, and a - syn
Slide 16: Intracellular Targeting for earliest pathology intervention
Intracellular Targeting for earliest pathology intervention in NDD 1 Brain penetrant small molecules as a key differentiator Conformation - specific and highly selective for misfolded forms of target proteins in NDD, i.e. Tau, a - syn 2 and TDP - 43 3 3 Potential application across all pathological
Slide 17: Intracellular Targeting pipeline focused on neurodegenerative diseases
Candidate Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 ACI - 19764 Neuro - inflammation ( NLRP3 1 ) Morphomer ® Tau Alzheimer's disease ( Tau ) Morphomer ® a - syn 2 Parkinson’s disease ( a - syn ) Intracellular Targeting pipeline focused on neurodegenerative diseases Programs now close
Slide 18: Key milestones 2026
4. Key milestones 2026
Slide 19: Key milestones 2026: Multiple catalysts across pipeline
H2 2026 H1 2026 Active immunotherapies ABATE Phase 2 trial in AD 1 : first patient dosed in AD4 cohort Abeta ACI - 24 (Takeda) ABATE Phase 2 trial readouts after 12 months of treatment (AD3: Abeta PET) Discussions with regulators regarding clinical development plan a - syn 3 ACI - 7104 Phase 2 VacSY
Slide 20: Financial figures
5. Financial figures
Slide 21: 2025 Financial Overview
2025 Financial Overview Key financial data (IFRS) (1) Liquidity is defined as the cash and cash equivalents plus short - term financial assets. These short - term financial assets are cash held in fixed - term deposits ranging in maturity from 3−12 months 21 NASDAQ: ACIU | AGM Presentation, June 11,
Slide 22: AC Immune strong Balance Sheet
AC Immune strong Balance Sheet Operations well - funded into Q4 2027 Investment strategy focused on major value drivers and near - term catalysts Strong Balance Sheet 2 Cash runway into Q4 2027 2026 annual cash burn guidance CHF 55m – 65m Cash of CHF 74.8 million 1 (1) As of March 31, 2026; (2) Assu
Slide 23: Summary and Strategic outlook
6. Summary and Strategic outlook
Slide 24: Creating the future of Precision Medicine in neurodegeneration
Creating the future of Precision Medicine in neurodegeneration The foundation for early detection and treatment Cash runway enables achievement of key milestones & execution of value - generating innovation Advance clinical - stage active immunotherapies Financial position (1) Phase 1b/2; (2) Phase
Slide 25: Pioneering Precision Prevention
Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention 25 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission Pioneering Precision Prevention
Slide 26: Agenda items and proposals of the Board of Directors
7. Agenda items and proposals of the Board of Directors
Slide 27: Approval of 2025 IFRS Consolidated and Statutory Financial Statements
Agenda item 1 27 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 2025 IFRS Consolidated Financial Statements, 2025 Statutory Financial Statements, 2025 Compensation Report 1. Approval of 2025 IFRS Consolidated Financial Statements and
Slide 28: Advisory Vote on the 2025 Compensation Report
Agenda item 1 28 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 2025 IFRS Consolidated Financial Statements, 2025 Statutory Financial Statements, 2025 Compensation Report 1.2 Advisory Vote on the 2025 Compensation Report ■ The Board p
Slide 29: Appropriation of Losses
Agenda item 2 Appropriation of Losses 29 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission ■ The Board proposes the following appropriation of losses: In CHF K (356,846) Accumulated profit (loss) at Jan 1, 2025 (67,595) Net profit (loss)
Slide 30: Discharge of the Board of Directors and Executive Management
Agenda item 3 Discharge of the Members of the Board of Directors and the Executive Management 30 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission ■ The Board proposes that all Members of the Board and of the Executive Management be disc
Slide 31: Compensation for the Board of Directors
Agenda item 4 Compensation for the Members of the Board of Directors and the Executive Management 31 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 1. Binding Vote on Maximum Aggregate Compensation for Members of the Board of Director
Slide 32: Compensation for the Executive Management
Agenda item 4 Compensation for the Members of the Board of Directors and the Executive Management 32 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 2. Binding Vote on Maximum Aggregate Compensation for Members of the Executive Managem
Slide 33: Re-Elections of Members and the Chair of the Board
Agenda item 5 Re - Elections 33 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 1. Re - Elections of Members and the Chair of the Board of Directors ■ The Board proposes that each of the following persons be re - elected for a term of
Slide 34: Re-Elections of Compensation, Nomination and Corporate Governance Committee
Agenda item 5 Re - Elections 34 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 2. Re - Elections of Members of the Compensation, Nomination and Corporate Governance Committee ■ The Board proposes that: ■ Monika Bütler ■ Roy Twyman be
Slide 35: Re-Election of the Statutory Auditors
Agenda item 5 Re - Elections 35 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 5.3 Re - Election of the Statutory Auditors ■ The Board proposes that PricewaterhouseCoopers SA, in Lausanne, Switzerland, be re - elected as Statutory Aud
Slide 36: Re-Election of the Independent Proxy
Agenda item 5 Re - Elections 36 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 4. Re - Election of the Independent Proxy ■ The Board proposes that Reymond & Associés Attorneys in Lausanne, Switzerland be re - elected as Independent Pr
Slide 37: Changes in the Articles of Association: Capital Band
Agenda item 6 Changes in the Articles of Association 37 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 1. Capital Band (Article 3a) ■ The Board proposes to introduce a capital band with an upper limit of CHF 2,862,500.00 and a lower l
Slide 38: Increase of Conditional Share Capital for Employee-Benefit Plans
Agenda item 6 Changes in the Articles of Association 38 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 2. Increase of Conditional Share Capital for Employee - Benefit Plans (Art. 3c) ■ The Board proposes to increase the conditional sh
Slide 39: We thank you for your attendance and your continued support
We thank you for your attendance and your continued support. 39 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission
Slide 40: Back-up
Back - up
Slide 41: Proposed Article 3a
Agenda item 6.1 Proposed Article 3a 41 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 1. The Company has a capital band ranging from CHF 2,202,018.50 corresponding to 110,100,925 registered shares with a par value of CHF 0.02 each, to
Slide 42: Proposed Article 3a (cont'd)
Agenda item 6.1 Proposed Article 3a (cont’d) 42 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 3. The subscription to and acquisition of new registered shares and any subsequent transfers of their ownership shall be subject to the res
Slide 43: Proposed Article 3c
Agenda item 6.2 Proposed Article 3c 43 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 1. The share capital of the Company shall be increased by an amount not exceeding CHF 150,000.00 through the issue of a maximum of 7,500,000 registe